CN114667154A - 用于改善针对非允许性癌症的溶瘤病毒感染的方法和组合物 - Google Patents

用于改善针对非允许性癌症的溶瘤病毒感染的方法和组合物 Download PDF

Info

Publication number
CN114667154A
CN114667154A CN202080076789.2A CN202080076789A CN114667154A CN 114667154 A CN114667154 A CN 114667154A CN 202080076789 A CN202080076789 A CN 202080076789A CN 114667154 A CN114667154 A CN 114667154A
Authority
CN
China
Prior art keywords
oncolytic virus
virus
cancer
inhibitor
mass transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080076789.2A
Other languages
English (en)
Chinese (zh)
Inventor
道格拉斯·格兰特·麦克法登
穆罕默德·马斯姆杜尔·拉赫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona's Public Universities
Original Assignee
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona's Public Universities filed Critical Arizona's Public Universities
Publication of CN114667154A publication Critical patent/CN114667154A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080076789.2A 2019-09-02 2020-09-01 用于改善针对非允许性癌症的溶瘤病毒感染的方法和组合物 Pending CN114667154A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894929P 2019-09-02 2019-09-02
US62/894,929 2019-09-02
US201962913667P 2019-10-10 2019-10-10
US62/913,667 2019-10-10
PCT/US2020/048932 WO2021046048A1 (en) 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Publications (1)

Publication Number Publication Date
CN114667154A true CN114667154A (zh) 2022-06-24

Family

ID=74853433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076789.2A Pending CN114667154A (zh) 2019-09-02 2020-09-01 用于改善针对非允许性癌症的溶瘤病毒感染的方法和组合物

Country Status (9)

Country Link
US (1) US12691151B2 (enExample)
EP (1) EP4025230B1 (enExample)
JP (2) JP2022546985A (enExample)
KR (1) KR20220054865A (enExample)
CN (1) CN114667154A (enExample)
AU (1) AU2020340934A1 (enExample)
CA (1) CA3152787A1 (enExample)
IL (1) IL290974A (enExample)
WO (1) WO2021046048A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077505A (zh) * 2023-01-17 2023-05-09 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134134A1 (en) * 2005-03-07 2014-05-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431349A1 (en) 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134134A1 (en) * 2005-03-07 2014-05-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CYNTHIA MATHEW AND REENA GHILDYAL: "CRM1 inhibitors for antiviral therapy", FRONTIERS IN MICROBIOLOGY *
REBECCA A. BACHMANN1: "A Nuclear Transport Signal in Mammalian Target of Rapamycin Is Critical for Its Cytoplasmic Signaling to S6 Kinase 1*", JOURNAL OF BIOLOGICAL CHEMISTRY *
W. RIAZ, N. BURKE AND A. MAHIPAL: "Selinexor.Exportin-1(XPO1) inhibitor, Oncolytic", DRUGS OF THE FUTURE, pages 685 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077505A (zh) * 2023-01-17 2023-05-09 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用
CN116077505B (zh) * 2023-01-17 2024-09-06 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用

Also Published As

Publication number Publication date
WO2021046048A1 (en) 2021-03-11
AU2020340934A1 (en) 2022-03-31
EP4025230A4 (en) 2023-10-04
JP2025028853A (ja) 2025-03-05
CA3152787A1 (en) 2021-03-11
US12691151B2 (en) 2026-07-28
JP2022546985A (ja) 2022-11-10
KR20220054865A (ko) 2022-05-03
EP4025230B1 (en) 2025-11-05
IL290974A (en) 2022-05-01
EP4025230A1 (en) 2022-07-13
US20220296660A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
EP4025230B1 (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
Smee et al. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir
US9987315B2 (en) Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
Wu et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting
AU2004216928A1 (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US12398375B2 (en) Methods for improved poxvirus yields
Garza et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit model
Ndayambaje et al. Plant-derived molecules in monkeypox management: insight and alternative therapeutic strategies
HK40076417A (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
US20250387443A1 (en) Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways
US20250249056A1 (en) Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus
Remichkova Poxviruses: Smallpox vaccine, its complications and chemotherapy
US11591616B1 (en) Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
US20080299131A1 (en) Anti-Viral Compositions
CN120661503A (zh) 一种治疗鸡传染性法氏囊病的药物
Singh A comparison of both water and ethanol extracts prepared from Echinacea purpurea and Echinacea angustifolia on the response to Influenza A/PR/8/34 infection in mice
CN121489935A (zh) 山荷叶素在抑制痘病毒及预防或治疗痘病毒感染的药物制备中的应用
CN120093750A (zh) 石蒜碱在制备预防或治疗痘病毒感染相关疾病的药物中的应用
Rehm The poxvirus A35 protein promotes virulence by regulating the host adaptive immune response
Holechek Lessons from Vaccinia Virus Post-Exposure Prophylaxis: Insights into Control of Diseases and Epidemics
Mathew et al. Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated
Knorr Characterization of cytokine induction and effects of antiviral treatment in four murine models of poxvirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076417

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220624